出生第一周内启动抗逆转录病毒治疗的安全性与有效性
博茨瓦纳早期婴儿治疗研究在出生96小时内检测HIV暴露婴儿,HIV感染婴儿在出生<7天启动奈韦拉平/齐多夫定/拉米夫定。40名婴儿中位2天龄启动,奈韦拉平谷浓度波动大且50%的2周测量低于治疗目标,但方案安全有效,12周55%病毒载量<40拷贝/mL,24周71%<40拷贝/mL。
要点
- 出生第一周内启动NVP/ZDV/3TC方案安全有效,即使NVP谷浓度低于目标。
- 12周55%婴儿HIV RNA<40拷贝/mL,24周71%<40拷贝/mL。
- 过渡到LPV/r后22.5%出现短暂病毒载量升高,可能与LPV/r口感差有关。
核心结论
- 出生第一周内启动NVP/ZDV/3TC安全有效,即使NVP谷浓度低于治疗目标;过渡到LPV/r后出现短暂病毒升高,但12和24周多数儿童实现并维持病毒抑制。
研究设计与样本
- 博茨瓦纳早期婴儿治疗研究,在出生96小时内检测HIV暴露婴儿,HIV感染婴儿在出生<7天启动NVP 6 mg/kg每日两次、ZDV和3TC。
- 40名HIV感染婴儿中位启动年龄2天(范围1-5天),在1和2周检测NVP谷浓度,并根据出生胎龄在2、3、4或5周将NVP转换为洛匹那韦/利托那韦(LPV/r)。
主要发现
- NVP谷浓度高度可变,50%的2周测量低于治疗目标(3000 ng/mL),浓度与第2、4、12周病毒下降不相关。
- 截至24周发生2例与ART无关的死亡,仅需1次非计划治疗调整。
- 过渡到LPV/r后4周内,9例(22.5%)出现短暂HIV RNA升高,可能因LPV/r口感差。
- 12周时40例中22例(55%)<40拷贝/mL(93%<400拷贝/mL);24周时38例中27例(71%)<40拷贝/mL(84%<400拷贝/mL)。
- 12和24周HIV-1 RNA应答与基线HIV RNA或其他因素无关。
临床怎么用
- 对于出生第一周内确诊HIV感染的婴儿,可考虑启动NVP/ZDV/3TC方案,即使NVP谷浓度低于目标仍可能有效。
- 过渡到LPV/r时需警惕短暂病毒载量升高,并关注LPV/r口感问题对依从性的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Early antiretroviral therapy (ART) is recommended for infants with human immunodeficiency virus (HIV) infection. However, few antiretroviral options are available for neonates. METHODS: The Early Infant Treatment Study in Botswana tested HIV-exposed infants within 96 hours of birth, and HIV-infected infants started nevirapine (NVP) 6 mg/kg twice daily, zidovudine (ZDV), and lamivudine (3TC) at age < 7 days. NVP trough concentrations were tested at 1 and 2 weeks. NVP was switched to ritonavir-boosted lopinavir (LPV/r) at week 2, 3, 4, or 5 according to delivery gestational age. RESULTS: Forty HIV-infected infants started ART at median age 2 days (range, 1-5 days). NVP trough concentrations were highly variable and below therapeutic target (3000 ng/mL) for 50% of 2-week measurements; concentrations did not correlate with viral decline at weeks 2, 4, or 12. Two deaths unrelated to ART occurred through 24 weeks. Only 1 unscheduled treatment modification was required. Within 4 weeks of transition to LPV/r, 9 (22.5%) had transient HIV RNA increases, likely due to poor LPV/r palatability. At 12 weeks, 22 (55%) of 40 were <40 copies/mL (93% <400 copies/mL); by 24 weeks, 27 of 38 (71%) were < 40 copies/mL (84% < 400 copies/mL). HIV-1 RNA response at 12 and 24 weeks did not differ by baseline HIV RNA or other factors. CONCLUSIONS: NVP/ZDV/3TC started in the first week of life was safe and effective, even when trough NVP levels were below target. Transient viral increases occurred following transition to LPV/r, but by 12 and 24 weeks most children achieved and maintained viral suppression. CLINICAL TRIALS REGISTRATION: NCT02369406.
引用
- Maswabi K, Ajibola G, Bennett K, et al. Safety and Efficacy of Starting Antiretroviral Therapy in the First Week of Life. Clin Infect Dis. 2021. PMID: 31927562. doi:10.1093/cid/ciaa028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。